Cyto Dyn
Biotechnology, 1111 Main St Ste 660, VANCOUVER, Washington, 98660, United States, 11-50 Employees
Phone Number: 36********
Who is CYTODYN
CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncol...
Read More
-
Headquarters: 1111 Main St Ste 660, VANCOUVER, Washington, 98660, United States
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
CytoDyn Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CytoDyn
Answer: CytoDyn's headquarters are located at 1111 Main St Ste 660, VANCOUVER, Washington, 98660, United States
Answer: CytoDyn's phone number is 36********
Answer: CytoDyn's official website is https://cytodyn.com
Answer: CytoDyn's revenue is $5 Million to $10 Million
Answer: CytoDyn's SIC: 2834
Answer: CytoDyn's NAICS: 325412
Answer: CytoDyn has 11-50 employees
Answer: CytoDyn is in Biotechnology
Answer: CytoDyn contact info: Phone number: 36******** Website: https://cytodyn.com
Answer: CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation. Leronlimab is a humanized monoclonal antibody that is a once-a-week subcutaneous injection that can also be administered intravenously. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. This mechanism of action of binding competitively to the CCR5 receptor differentiates leronlimab from all other CCR5 antagonists.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month